Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,752 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,757 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,046)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02323126 | Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer | terminated | Phase 2 | 64 | Novartis PharmaceuticalsINDUSTRY | 8 | Feb 28, 2022 | clinicaltrials |
| NCT04958993 | A Trial of Anlotinib Combined With Concurrent Chemoradiotherapy in Patients With Unresectable Stage III Non-small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 7 | Shandong Cancer Hospital and InstituteOTHER | 1 |
| Feb 25, 2022 |
| clinicaltrials |
| NCT02963610 | Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 3 | Fox Chase Cancer CenterOTHER | 1 | Dec 30, 2021 | clinicaltrials |
| NCT00372073 | Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer | terminated | Phase 2 | 187 | Cyclacel Pharmaceuticals, Inc.INDUSTRY | 1 | Dec 22, 2021 | clinicaltrials |
| NCT00885963 | A Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer | terminated | Phase 2 | 62 | Cyclacel Pharmaceuticals, Inc.INDUSTRY | 1 | Dec 22, 2021 | clinicaltrials |
| NCT00960297 | Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLC | terminated | Phase 2 | 4 | SCRI Development Innovations, LLCOTHER | 1 | Dec 6, 2021 | clinicaltrials |
| NCT04165031 | A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation | terminated | Phase 1 / Phase 2 | 5 | Eli Lilly and CompanyINDUSTRY | 2 | Nov 24, 2021 | clinicaltrials |
| NCT01741155 | Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer (NSCLC) | terminated | Phase 2 | 34 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Oct 13, 2021 | clinicaltrials |
| NCT02387216 | A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC(SHERLOC) | terminated | Phase 2 | 153 | Elevation OncologyINDUSTRY | 6 | Oct 12, 2021 | clinicaltrials |
| NCT03131206 | A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer | terminated | Phase 1 / Phase 2 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 27, 2021 | clinicaltrials |
| NCT02408016 | Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma | terminated | Phase 1 / Phase 2 | 11 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 13, 2021 | clinicaltrials |
| NCT01108666 | Proton Beam Radiation With Concurrent Chemotherapy and Nelfinavir for Inoperable Stage III Non Small Cell Lung Cancer (NSCLC) | terminated | Phase 2 | 7 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jul 7, 2021 | clinicaltrials |
| NCT02349633 | Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M) | terminated | Phase 1 / Phase 2 | 65 | PfizerINDUSTRY | 4 | Jun 10, 2021 | clinicaltrials |
| NCT02621333 | Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung Adenocarcinoma | terminated | Phase 2 | 280 | Henan Cancer HospitalOTHER_GOV | 1 | May 12, 2021 | clinicaltrials |
| NCT03644823 | Combinatory ImmunoTherapy-1 (Com-IT-1) Irradiation and PD-1 Blockade in Locally Advanced / Advanced NSCLC(COM-IT-1) | terminated | Phase 2 | 21 | Oslo University HospitalOTHER | 1 | Mar 30, 2021 | clinicaltrials |
| NCT02132598 | Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases | terminated | Phase 2 | 5 | Liza Villaruz, MDOTHER | 1 | Mar 10, 2021 | clinicaltrials |
| NCT03256721 | Compare Apatinib Plus Chemotherapy Drug Versus Chemotherapy Drug as Second-line Treatment in NSCLC | terminated | Phase 2 | 37 | Fuzhou General HospitalOTHER | 1 | Feb 8, 2021 | clinicaltrials |
| NCT02485652 | Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung | terminated | Phase 2 | 162 | Hanmi Pharmaceutical Company LimitedINDUSTRY | 10 | Jan 22, 2021 | clinicaltrials |
| NCT03382899 | Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer(Cypress 1) | terminated | Phase 2 | 101 | Eli Lilly and CompanyINDUSTRY | 1 | Jan 20, 2021 | clinicaltrials |
| NCT04170959 | The Addition of Metformin to Definitive Radiotherapy in Patients With Stage III NSCLC(RADFORMIN) | terminated | Phase 2 | 3 | ethisch.comite@uza.beOTHER | 1 | Jan 15, 2021 | clinicaltrials |
| NCT00760929 | A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC). | terminated | Phase 2 | 171 | Hoffmann-La RocheINDUSTRY | 11 | Jan 5, 2021 | clinicaltrials |
| NCT01268059 | A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Untreated, Advanced Non-Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 99 | MedImmune LLCINDUSTRY | 7 | Dec 23, 2020 | clinicaltrials |
| NCT00794417 | A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Participants With Advanced Carcinoma | terminated | Phase 1 / Phase 2 | 60 | Regeneron PharmaceuticalsINDUSTRY | 2 | Dec 10, 2020 | clinicaltrials |
| NCT04044170 | Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation | terminated | Phase 2 | 5 | Hanmi Pharmaceutical Company LimitedINDUSTRY | 2 | Nov 17, 2020 | clinicaltrials |
| NCT03302247 | Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy | terminated | Phase 2 | 3 | Fox Chase Cancer CenterOTHER | 1 | Oct 28, 2020 | clinicaltrials |
| NCT03724253 | [68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR)(NeoFIND) | terminated | Phase 2 | 19 | Advanced Accelerator ApplicationsINDUSTRY | 2 | Oct 23, 2020 | clinicaltrials |
| NCT02318368 | A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label(FOCAL) | terminated | Phase 2 | 10 | AVEO Pharmaceuticals, Inc.INDUSTRY | 7 | Oct 22, 2020 | clinicaltrials |
| NCT01188707 | A Trial of Belinostat in Combination With Erlotinib in Patients With Non-small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 5 | Herlev HospitalOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT02642939 | Study of Oral Mifepristone as Salvage Therapy in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer | terminated | Phase 2 | 3 | Check, Jerome H., M.D., Ph.D.INDIV | 1 | Oct 19, 2020 | clinicaltrials |
| NCT03382912 | Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer(Cypress 2) | terminated | Phase 2 | 52 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 11, 2020 | clinicaltrials |
| NCT02147990 | Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer(NSCLC) | terminated | Phase 2 | 318 | Clovis Oncology, Inc.INDUSTRY | 12 | Aug 12, 2020 | clinicaltrials |
| NCT01526928 | Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients | terminated | Phase 1 / Phase 2 | 612 | Clovis Oncology, Inc.INDUSTRY | 4 | Aug 4, 2020 | clinicaltrials |
| NCT02193152 | Pazopanib in Molecularly Selected Patients With Advanced NSCLC | terminated | Phase 2 | 16 | Washington University School of MedicineOTHER | 1 | Jul 14, 2020 | clinicaltrials |
| NCT01857271 | Erlotinib Hydrochloride Before Surgery in Treating Patients With Stage III Non-Small Cell Lung Cancer(EVENT) | terminated | Phase 2 | 3 | Albert Einstein College of MedicineOTHER | 1 | Jul 8, 2020 | clinicaltrials |
| NCT03411473 | Study of AGEN1884 With Pembrolizumab in 1L NSCLC | terminated | Phase 2 | 2 | Agenus Inc.INDUSTRY | 2 | Jun 2, 2020 | clinicaltrials |
| NCT00420732 | Vaccine Maintenance Treatment for Non-Small Cell Lung Cancer | terminated | Phase 2 | 6 | NewLink Genetics CorporationINDUSTRY | 1 | May 28, 2020 | clinicaltrials |
| NCT01774578 | Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer | terminated | Phase 2 / Phase 3 | 135 | NewLink Genetics CorporationINDUSTRY | 1 | May 28, 2020 | clinicaltrials |
| NCT02452463 | Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation Therapy | terminated | Phase 2 | 8 | Roswell Park Cancer InstituteOTHER | 1 | Apr 6, 2020 | clinicaltrials |
| NCT02926638 | Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches | terminated | Phase 2 / Phase 3 | 9 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 19, 2020 | clinicaltrials |
| NCT03574818 | Necitumumab in the Neoadjuvant Setting With Gemcitabine in Surgically Resectable - 14X-US-I001 | terminated | Phase 2 | 1 | Montefiore Medical CenterOTHER | 1 | Mar 18, 2020 | clinicaltrials |
| NCT01717482 | Metformin as a Chemoprevention Agent in Non-small Cell Lung Cancer | terminated | Phase 2 | 6 | Mayo ClinicOTHER | 1 | Mar 10, 2020 | clinicaltrials |
| NCT02452424 | A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors | terminated | Phase 1 / Phase 2 | 78 | Daiichi SankyoINDUSTRY | 1 | Mar 5, 2020 | clinicaltrials |
| NCT02134912 | S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib | terminated | Phase 2 | 1 | SWOG Cancer Research NetworkNETWORK | 1 | Feb 20, 2020 | clinicaltrials |
| NCT02469701 | Advanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For Metastatic Disease | terminated | Phase 2 | 10 | howard safranOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT01392352 | HYPAZ: Hypertension Induced by Pazopanib(HYPAZ) | terminated | Phase 2 | 31 | Cambridge University Hospitals NHS Foundation TrustOTHER | 1 | Feb 13, 2020 | clinicaltrials |
| NCT02117024 | A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer | terminated | Phase 2 | 66 | Heat BiologicsINDUSTRY | 1 | Feb 5, 2020 | clinicaltrials |
| NCT03232892 | Trametinib in Patients With Advanced Neurofibromatosis Type 1 (NF1)-Mutant Non-small Cell Lung Cancer | terminated | Phase 2 | 1 | University of California, San FranciscoOTHER | 1 | Dec 3, 2019 | clinicaltrials |
| NCT00923273 | Sirolimus and Pemetrexed to Treat Non-Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 42 | National Cancer Institute (NCI)NIH | 1 | Nov 26, 2019 | clinicaltrials |
| NCT02770014 | Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer | terminated | Phase 2 | 43 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 22, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Feb 28, 2022source: clinicaltrials